- Stocks
- Pharma & Healthcare
- Krebs Biochemicals and Industries
Krebs Biochemicals and Industries share price
NSE: KREBSBIOPharma & HealthcareDrug Manufacturers - Specialty & Generic
Krebs Biochemicals and Industries at a glance
Krebs Biochemicals and Industries (NSE: KREBSBIO) closed at ₹56.59 on 22 Oct 2026, up 0.78% on the day. With a market capitalisation of ₹122 Cr, it ranks 2547th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was 0.0% in FY26. Over the past year the share price has fallen 19.3%. Its 52-week range is ₹38.33 (30 Mar 2026) to ₹76.85 (5 Dec 2025); the last close is 26.4% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹7 Cr (+27.4% year on year) and net profit −₹2 Cr, on a standalone basis. Promoters held 72.74% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹122 CrRank 2547 on NSE
- Price to book
- -0.53×FY26
- EPS (TTM)
- −₹6.54to Q1 FY27
- ROE
- 0.0%FY26
- ROCE
- −19.6%FY26
- Debt to equity
- -1.38FY26
- Net profit margin
- −71.4%FY26
- Book value / share
- −₹75.49FY26
- 52-week high
- ₹76.855 Dec 2025
- 52-week low
- ₹38.3330 Mar 2026
- 1-year return
- −19.3%
- RSI (14-day)
- 46.3
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +0.78% | −4.8% | +0.6% | +6.0% | −19.3% |
Krebs Biochemicals and Industries quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹13 Cr | ₹11 Cr | ₹6 Cr | ₹5 Cr | ₹4 Cr | ₹7 Cr | ₹7 Cr | ₹7 Cr |
| Revenue YoY | −13.6% | −11.6% | −49.0% | −57.5% | −67.6% | −36.6% | +11.6% | +27.4% |
| Net profit | −₹6 Cr | −₹8 Cr | −₹8 Cr | −₹5 Cr | −₹6 Cr | −₹3 Cr | −₹2 Cr | −₹2 Cr |
| Net profit YoY | — | — | — | — | — | — | — | — |
| Net margin | −44.8% | −67.5% | −135.6% | −97.1% | −147.2% | −43.1% | −34.4% | −35.5% |
| EPS | −₹2.67 | −₹3.59 | −₹3.83 | −₹2.47 | −₹2.85 | −₹1.45 | −₹1.09 | −₹1.15 |
Krebs Biochemicals and Industries financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹54 Cr | ₹60 Cr | ₹52 Cr | ₹50 Cr | ₹43 Cr | — |
| Operating profit | −₹28 Cr | −₹45 Cr | −₹25 Cr | −₹20 Cr | −₹27 Cr | — |
| Net profit | −₹28 Cr | −₹45 Cr | −₹25 Cr | −₹20 Cr | −₹27 Cr | — |
| EPS (₹) | −₹14.53 | −₹20.81 | −₹11.30 | −₹9.16 | −₹12.49 | — |
| Cash from operations | −₹15 Cr | −₹17 Cr | −₹25 Cr | ₹2 Cr | −₹8 Cr | — |
| Total debt | ₹101 Cr | ₹3 Cr | ₹43 Cr | ₹54 Cr | ₹31 Cr | ₹164 Cr |
| Shareholders' equity | −₹43 Cr | ₹55 Cr | ₹31 Cr | ₹11 Cr | −₹16 Cr | −₹163 Cr |
Krebs Biochemicals and Industries shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 72.74% | 72.74% | 72.74% | 72.74% | 72.74% | 72.74% |
| Foreign institutions | 0.50% | 0.50% | 0.50% | 0.50% | 0.50% | 0.50% |
| Non-institutions | 26.76% | 26.76% | 26.76% | 26.76% | 26.76% | 26.76% |
Krebs Biochemicals and Industries vs peers
The listed Pharma & Healthcare companies nearest to Krebs Biochemicals and Industries by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| LACTOSELactose India | — | — | — | ₹132 Cr | — | — |
| VALENCIAValencia Nutrit | — | — | — | ₹132 Cr | — | — |
| PARPar Drugs And Chemicals | ₹102.90 | −2.00% | +1.9% | ₹127 Cr | 9.7 | — |
| ASPIRAAspira Pathlab | — | — | — | ₹125 Cr | — | — |
| KREBSBIOKrebs Biochemicals and Industries | ₹56.59 | +0.78% | −19.3% | ₹122 Cr | — | — |
| GODAVARIGodavari Drugs | — | — | — | ₹120 Cr | — | — |
| PARNAXLABParnax Lab | ₹104.00 | −4.54% | — | ₹119 Cr | 10.1 | — |
Ask anything about Krebs Biochemicals and Industries
Pivot answers on the live chart with evidence you can check, and tests strategies against KREBSBIO's own history. Try: “Why has KREBSBIO moved over the last three months?” · “Backtest a 50-day moving-average crossover on KREBSBIO over five years” · “Compare KREBSBIO with LACTOSE on margins and valuation”
Frequently asked questions about Krebs Biochemicals and Industries
What is the share price of Krebs Biochemicals and Industries today?
Krebs Biochemicals and Industries (NSE: KREBSBIO) last closed at ₹56.59 on 22 Oct 2026. Its 52-week high is ₹76.85 and its 52-week low is ₹38.33.
What is the market cap of Krebs Biochemicals and Industries?
Krebs Biochemicals and Industries' market capitalisation is ₹122 Cr (₹122 Cr) at the 22 Oct 2026 close, ranking 2547th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Krebs Biochemicals and Industries?
Return on equity was 0.0% in FY26 and return on capital employed was −19.6% in FY26 (standalone figures).
Is Krebs Biochemicals and Industries a debt-free company?
Krebs Biochemicals and Industries is close to debt-free: its debt-to-equity ratio was -1.38 in FY26.
What were Krebs Biochemicals and Industries' latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Krebs Biochemicals and Industries reported revenue of ₹7 Cr, +27.4% year on year, and net profit of −₹2 Cr.
How has Krebs Biochemicals and Industries stock performed over the last year?
Krebs Biochemicals and Industries' share price has fallen 19.3% over the past year, +6.0% over three months and +0.6% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Krebs Biochemicals and Industries?
As of 30 Jun 2026: promoters 72.74%, foreign institutions 0.50%, non-institutions 26.76%.
Who are Krebs Biochemicals and Industries' competitors?
The listed Pharma & Healthcare companies closest to Krebs Biochemicals and Industries by market cap are Lactose India, Valencia Nutrit, Par Drugs And Chemicals, Aspira Pathlab, Godavari Drugs and Parnax Lab.
Is Krebs Biochemicals and Industries a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Krebs Biochemicals and Industries' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on KREBSBIO against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with K · all NSE stocks · this page as text